Endovascular Transvenous Versus Open Femoropopliteal Bypass

Overview

Journal Medicina (Kaunas)

Publisher MDPI

Specialty General Medicine

Date 2024 May 25

PMID 38792960

Authors

Roberts Rumba

Dainis Krievins

Natalija Ezite

Aigars Lacis

Ludovic Mouttet

Anda L Vavere

Christopher K Zarins

Affiliations

Soon will be listed here.

Abstract

: Lower extremity arterial disease is one of the most prevalent manifestations of atherosclerosis. The results from numerous studies regarding the best revascularization method of an occluded superficial femoral artery have been conflicting. The aim of this study was to compare the patency of transvenous endovascular with open femoropopliteal bypass, both with vein and prosthetic grafts. To our knowledge, a direct patency comparison between transvenous endovascular and open femoropopliteal bypass has not been published. This could help elucidate which method is preferable and in which cases. : Patients with complex TASC-C and D SFA lesions were offered endovascular transvenous or open bypass. A total of 384 consecutive patients with PAD requiring surgical treatment were evaluated for inclusion in this study. Three-year follow-up data were collected for 52 endovascular procedures, 80 prosthetic grafts, and 44 venous bypass surgeries. Bypass patency was investigated by Duplex US every 6 months. Kaplan-Meier plots were used to analyze primary, primary-assisted, and secondary patency for endovascular transvenous, autovenous, and prosthetic bypasses. : Primary, primary-assisted, and secondary patency in venous group at 3 years was 70.5%, 77.3%, and 77.3%, respectively. In the endovascular transvenous group, primary, primary-assisted, and secondary patency at 3 years was 46.2%, 69.2%, and 76.9%, respectively. The lowest patency rates at 3 years were noted in the prosthetic graft group with 22.5% primary, 26.6% primary-assisted, and 28.2% secondary patency. : The saphenous vein is the best graft to perform in above-the-knee femoropopliteal bypass. Transvenous endovascular bypass is a viable option with comparable primary-assisted and secondary patency. Primary patency is substantially lower for endovascular transvenous compared to venous bypass. Patients treated with endovascular transvenous bypass will require a significant number of secondary procedures to provide optimal patency. Prosthetic grafts should only be used if no other option for bypass is available.

References

AbuRahma A . When Are Endovascular and Open Bypass Treatments Preferred for Femoropopliteal Occlusive Disease?. Ann Vasc Dis. 2018; 11(1):25-40. PMC: 5882358. DOI: 10.3400/avd.ra.18-00001. View

Ohki T, Kichikawa K, Yokoi H, Iida O, Yamaoka T, Maeda K . Long-term results of the Japanese multicenter Viabahn trial of heparin bonded endovascular stent grafts for long and complex lesions in the superficial femoral artery. J Vasc Surg. 2021; 74(6):1958-1967.e2. DOI: 10.1016/j.jvs.2021.05.056. View

Bradbury A, Adam D, Bell J, Forbes J, Fowkes F, Gillespie I . Bypass versus Angioplasty in Severe Ischaemia of the Leg (BASIL) trial: Analysis of amputation free and overall survival by treatment received. J Vasc Surg. 2010; 51(5 Suppl):18S-31S. DOI: 10.1016/j.jvs.2010.01.074. View

Rumba R, Krievins D, Savlovskis J, Ezite N, Lacis A, Petrosina E . Three-Year Patency Results following Endovascular Transvenous Femoropopliteal Bypass. Medicina (Kaunas). 2023; 59(3). PMC: 10059675. DOI: 10.3390/medicina59030462. View

Ambler G, Twine C . Graft type for femoro-popliteal bypass surgery. Cochrane Database Syst Rev. 2018; 2:CD001487. PMC: 6491197. DOI: 10.1002/14651858.CD001487.pub3. View

Bosiers M, De Donato G, Torsello G, Silveira P, Scheinert D, Veroux P . ZILVERPASS Study: ZILVER PTX Stent versus Prosthetic Above-the-Knee Bypass Surgery in Femoropopliteal Lesions, 5-year Results. Cardiovasc Intervent Radiol. 2023; 46(10):1348-1358. PMC: 10547807. DOI: 10.1007/s00270-023-03549-0. View

Krievins D, Halena G, Scheinert D, Savlovskis J, Szopinski P, Kramer A . One-year results from the DETOUR I trial of the PQ Bypass DETOUR System for percutaneous femoropopliteal bypass. J Vasc Surg. 2020; 72(5):1648-1658.e2. DOI: 10.1016/j.jvs.2020.02.043. View

Sarradon P, Ata Ozdemir B, Becquemin J . Technique and early results of percutaneous femoropopliteal bypass with stent graft. J Vasc Surg Cases Innov Tech. 2023; 9(4):101317. PMC: 10569994. DOI: 10.1016/j.jvscit.2023.101317. View

Lyons O, Behrendt C, Bjorck M . Beyond Wires and Knives: What Can We Learn From BEST-CLI and BASIL-2?. Eur J Vasc Endovasc Surg. 2023; 66(1):1-3. DOI: 10.1016/j.ejvs.2023.05.032. View

10.

Zenunaj G, Acciarri P, Baldazzi G, Cosacco A, Gasbarro V, Traina L . Endovascular Revascularisation versus Open Surgery with Prosthetic Bypass for Femoro-Popliteal Lesions in Patients with Peripheral Arterial Disease. J Clin Med. 2023; 12(18). PMC: 10532352. DOI: 10.3390/jcm12185978. View

11.

Nierlich P, Enzmann F, Metzger P, Dabernig W, Akhavan F, Ellacuriaga San Martin J . Arm Vein versus Small Saphenous Vein for Lower Extremity Bypass in the Absence of Both Great Saphenous Veins. Ann Vasc Surg. 2020; 70:341-348. DOI: 10.1016/j.avsg.2020.06.043. View

12.

Vossen R, Vahl A, Fokkema T, Leijdekkers V, van Swijndregt A, Balm R . Endovascular therapy versus femoropopliteal bypass surgery for medium-length TASC II B and C lesions of the superficial femoral artery: An observational propensity-matched analysis. Vascular. 2019; 27(5):542-552. DOI: 10.1177/1708538119837134. View

13.

Shamaki G, Markson F, Soji-Ayoade D, Agwuegbo C, Bamgbose M, Tamunoinemi B . Peripheral Artery Disease: A Comprehensive Updated Review. Curr Probl Cardiol. 2021; 47(11):101082. DOI: 10.1016/j.cpcardiol.2021.101082. View

14.

Shu H, Xiong X, Chen X, Sun X, Zhang R, Wang R . Endovascular revascularization vs. open surgical revascularization for patients with lower extremity artery disease: a systematic review and meta-analysis. Front Cardiovasc Med. 2023; 10:1223841. PMC: 10405177. DOI: 10.3389/fcvm.2023.1223841. View

15.

Sharrock M, Antoniou S, Antoniou G . Vein Versus Prosthetic Graft for Femoropopliteal Bypass Above the Knee: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Angiology. 2019; 70(7):649-661. DOI: 10.1177/0003319719826460. View

16.

Bradbury A, Moakes C, Popplewell M, Meecham L, Bate G, Kelly L . A vein bypass first versus a best endovascular treatment first revascularisation strategy for patients with chronic limb threatening ischaemia who required an infra-popliteal, with or without an additional more proximal infra-inguinal.... Lancet. 2023; 401(10390):1798-1809. DOI: 10.1016/S0140-6736(23)00462-2. View

17.

Farber A, Menard M, Conte M, Kaufman J, Powell R, Choudhry N . Surgery or Endovascular Therapy for Chronic Limb-Threatening Ischemia. N Engl J Med. 2022; 387(25):2305-2316. DOI: 10.1056/NEJMoa2207899. View

18.

Rumba R, Krievins D, Savlovskis J, Ezite N, Kukulis I, Petrosina E . Long term clinical and functional venous outcomes after endovascular transvenous femoro-popliteal bypass. Int Angiol. 2022; 41(6):509-516. DOI: 10.23736/S0392-9590.22.04937-9. View

19.

Kluckner M, Gruber L, Wippel D, Lobenwein D, Westreicher W, Pilz M . Long-Term Outcome of Bypass Surgery versus Endovascular Revascularization in Long Femoropopliteal Lesions. J Clin Med. 2023; 12(10). PMC: 10219229. DOI: 10.3390/jcm12103507. View

20.

Schneider P, Krievins D, Halena G, Schmidt A, Lyden S, Lee V . Venous outcomes at 1 year after using the femoral vein as a conduit for passage of percutaneous femoropopliteal bypass. J Vasc Surg Venous Lymphat Disord. 2021; 9(5):1266-1272.e3. DOI: 10.1016/j.jvsv.2020.12.080. View